Catalysts / CTMX
Upcoming FDA decisions and readouts we track for CytomX Therapeutics, each with the filing that announced it.
FreeBioList tracks 3 upcoming catalysts for CytomX Therapeutics (CTMX, listed on Nasdaq). They cover 3 programmes: Varseta-M (CX-2051) (Metastatic colorectal cancer (EpCAM ADC)), Varseta-M + bevacizumab (Metastatic colorectal cancer) and CX-801 + pembrolizumab (Advanced melanoma (masked interferon alpha-2b)).
First on the list: the Phase 1 readout for Varseta-M (CX-2051) (Metastatic colorectal cancer (EpCAM ADC)), guided by the company to Late 2026. The furthest-out event tracked is H1 2027. By stage, the upcoming rows are 3 Phase 1 readouts.
All 3 rows link to SEC filings (8-K or 6-K). All have been verified by a person reading the filing itself, most recently on 12 Sep 2026. The methodology page explains each status.
Background reading: Clinical trial phases explained: Phase 1 to Phase 4.
| Company ▾ | Drug ▾ | Effect / indication | Next catalyst ▾ | Phase / type ▾ | Status ▾ | Source | Options |
|---|---|---|---|---|---|---|---|
| CytomX Therapeutics CTMX · Nasdaq | Varseta-M (CX-2051) | Metastatic colorectal cancer (EpCAM ADC) | Late 2026 company guidance |
Phase 1 readout | Verified | 8-K exhibit 99.1 ↗ | Yes |
| CytomX Therapeutics CTMX · Nasdaq | Varseta-M + bevacizumab | Metastatic colorectal cancer | H1 2027 company guidance |
Phase 1 readout | Verified | 8-K exhibit 99.1 ↗ | Yes |
| CytomX Therapeutics CTMX · Nasdaq | CX-801 + pembrolizumab | Advanced melanoma (masked interferon alpha-2b) | H1 2027 company guidance |
Phase 1 readout | Verified | 8-K exhibit 99.1 ↗ | Yes |
FreeBioList